Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2013 | Pages:
94 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The global lung cancer diagnostics market is expected to reach USD 3,644.6 million by 2024, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies. Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer. Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation. Further key findings from the study suggest: The small cell lung cancer segment accounted for around 15% market share in 2015. This is an aggressive subtype of the lung malignancies, which has proven to be fatal within a short period of time if left undiagnosed. Non-small cell lung cancer was identified as the largest segment in 2015 with revenue of over USD 1,300.0 million. This is majorly due to the availability of novel lung cancer diagnostics that facilitate the detection of large tumor growths. The imaging tests segment was identified as the largest revenue generating segment in 2015 with a market share of around 50%. Major factors responsible for the large market share include the frequent use of various imaging techniques such as CT scan, X-ray, and MRI in the detection of lung malignancies coupled with the increased availability of the diagnostic tools. The molecular testing segment is expected to grow at a profitable rate of around 10% over the forecast period. The introduction of novel molecular testing techniques coupled with the increasing number of investments to support the research and development efforts for the development of biomarker-based molecular testing in lung cancer detection is expected to foster the demand of this segment over the forecast period. In 2015, North America accounted for the largest revenue share of over 30% majorly due to supportive government policies in the region coupled with the availability of technology-enabled lung cancer diagnostics Asia Pacific region is expected to reach a revenue share of over 28% by 2024. Major factors responsible for the growth include the constantly improving healthcare infrastructure, the growing awareness of the disease symptoms, and a wide base of unmet clinical needs in the developing countries in the region. Major players of this market include bioMerieux, Roche Diagnostics, Qiagen N.V., Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, Janssen, AstraZeneca plc, and Sanofi S.A. Novel product launches in the lung cancer diagnostics product portfolio is one of the major strategic initiatives adopted by the market players. For instance, Orion genomics is involved in the development of novel biomarkers for lung cancer diagnosis. Allegro Diagnostics is involved in the development and commercialization of pulmonary genomics-based lung cancer diagnostics.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
4.1 Market segmentation& scope
4.2 Market size and growth prospects
4.2.1 Market Driver Analysis
4.2.1.1 Rise in awareness about lung cancer symptoms
4.2.1.2 High cigarette consumption
4.2.1.3 Other drivers
4.2.2 Market Restraint Analysis
4.2.2.1 Cost of diagnosis
4.2.2.2 Lack of healthcare infrastructure
4.3 Penetration & growth prospect mapping
4.4 Lung Cancer Diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
4.5 Industry Analysis - Porter's
4.6 Lung cancer diagnostics company market share/competitive landscape, 2015
Chapter 5 Market Categorization 1: Lung Cancer Type Estimates & Trend Analysis
5.1 Lung cancer diagnostics market: Lung cancer type movement analysis
5.2 Small cell lung cancer (SCLC)
5.2.1 Small cell lung cancer diagnostics market, 2013 - 2024 (USD Million)
5.3 Non-small cell lung cancer (NSCLC)
5.3.1 Non-small cell lung cancer diagnostics market, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Diagnostic Test Estimates & Trend Analysis
6.1 Lung cancer diagnostics market: Application movement analysis
6.2 Imaging Test
6.2.1 Imaging test market, 2013 - 2024 (USD Million)
6.3 Sputum cytology
6.3.1 Sputum cytology market, 2013 - 2024 (USD Million)
6.4 Biopsy
6.4.1 Biopsy market, 2013 - 2024 (USD Million)
6.5 Molecular tests
6.5.1 Molecular tests market, 2013 - 2024 (USD Million)
6.6 Others
6.6.1 Other diagnostics market, 2013 - 2024 (USD Million)
Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Type & Test
7.1 Lung cancer diagnostics market share by region, 2015 & 2024
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Russia
7.3.2 Germany
7.4 Asia Pacific
7.4.1 China
7.4.2 India
7.5 Latin America
7.5.1 Brazil
7.6 MEA
7.6.1 South Africa
Chapter 8 Competitive Landscape
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Roche Diagnostics
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 bioMerieux
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Qiagen N.V.
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Thermo Fisher Scientific
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 Agilent Technologies
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 SanofiS.A.
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
List of Tables TABLE 1 North America lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 2 North America lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 3 U.S. lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 4 U.S. lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 5 Canada lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 6 Canada lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 7 Europe lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 8 Europe lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 9 Russia lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 10 Russia lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 11 Germany lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 12 Germany lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 13 Asia Pacific lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 14 Asia Pacific lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 15 China lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 16 China lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 17 India lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 18 India lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 19 Latin America lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 20 Latin America lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 21 Brazil lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 22 Brazil lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 23 MEA lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 24 MEA lung cancer diagnostics market, by test, 2013 - 2024 (USD Million) TABLE 25 South Africa lung cancer diagnostics market, by type, 2013 - 2024 (USD Million) TABLE 26 South Africa lung cancer diagnostics market, by test, 2013 - 2024 (USD Million)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
